Kayak and Palo Alto Take Off Day One Trading with a Bang

Palm Beach, FL 7/20/12 (StreetBeat) – Kayak (Nasdaq: KYAK), a household name for online hotel-and flight-search, jumped $4, or 16 percent, this morning to open at $30 a share.

The company sold shares last night at $26 a share, raising $100 million. At that price point, the company has a market valuation of $1 billion.

Only last week, Kayak had estimated it would sell 3.5 million shares between $22 and $25. The stock can be found on Nasdaq Exchange under the ticker symbol “KYAK.”

Kayak was founded in 2004 by Steve Hafner, Kayak’s CEO, and Paul English, Kayak’s CTO.

The IPO has been a long time in coming. The Norwalk, Conn.-based company filed nearly a year ago, but faced multiple delays as the economy sputtered. More recently, the offering was considered to be a possibility again after other companies, such as LinkedIn, Yelp, Angie’s List, Facebook and others, went public with varying degrees of success.

Palo Alto Networks (NYSE: PANW), a provider of Internet firewall technology, also started trading early this morning, jumping as much as 48 percent in its public debut.

Kayak had raised a combined $223 million over four rounds, including a mammoth $196 million round in 2007 from Sequoia Capital, General Catalyst Partners and Accel Partners, most of which was used to acquire rival SideStep for about $200 million in cash and stock.

Please contact www.thestreetbeat.com for interest in our latest investor relations platform the “CEO Interview Series” with its host Steve Kanaval. The package includes a one-on-one interview with a seasoned industry professional; published segment to our web site with embedded audio/video file; and a compressed file that can be easily e-mailed out to your current and/or potential investors. Please e-mail bflautt@gmail.com or call (662) 392-0740 for pricing and scheduling.

StreetBeat Disclaimer

Distributed by Viestly

Rambus Inc (Nasdaq: RMBS) Drops 15% After Q2 Report

Orlando, FL 7/20/12 (StreetBeat) – Rambus Inc. (Nasdaq: RMBS) missed Wall Street’s earnings targets by $.09 per share in its Q2 report, causing shares to plunge 15% to $4.43. The stock has dropped 37% in 2012, and the company cites 15% lower sales year over year on “decrease in contract revenue, lower royalties reported by certain licensees and expiration of a patent license agreement.”

According to Motley Fool, the company is spending less on expensive litigation campaigns than it used to, but operating costs are way up anyhow. This it due to Rambus’ trying its hand at growth by acquisition, incurring a variety of costs for the add-on operations. Rambus received its first royalty payment from a recent Broadcom agreement, but it wasn’t enough to balance out Rambus’ challenges.

Rambus is currently a one-star CAPs stock (out of five). The company plans to explore pathways such as its new LED lighting research, hoping for about 15% of its revenue out of that division in 2013.

Please contact www.thestreetbeat.com for interest in our latest investor relations platform the “CEO Interview Series” with its host Steve Kanaval. The package includes a one-on-one interview with a seasoned industry professional; published segment to our web site with embedded audio/video file; and a compressed file that can be easily e-mailed out to your current and/or potential investors. Please e-mail bflautt@gmail.com or call (662) 392-0740 for pricing and scheduling.

StreetBeat Disclaimer

Distributed by Viestly

Chipotle Mexican Grill (NYSE: CMG) Plunges on Slowing Sales

Northern, WI 7/20/12 (StreetBeat) – Chipotle Mexican Grill (NYSE: CMG) is the biggest loser on the NYSE, with shares trading down 22.6% after touching a low of $309.01 in morning trade. It lost almost a quarter of its market value Friday after announcing a slower sales growth in Q2.

"We continue to worry about slower growth in the second half of 2012 (in the absence of) additional menu pricing, acceleration in multiyear traffic trends, or a positive margin surprise," BMO Capital Markets analyst Phillip Juhan, who cut his target price to $410 from $440, wrote in a client note.

Please contact www.thestreetbeat.com for interest in our latest investor relations platform the “CEO Interview Series” with its host Steve Kanaval. The package includes a one-on-one interview with a seasoned industry professional; published segment to our web site with embedded audio/video file; and a compressed file that can be easily e-mailed out to your current and/or potential investors. Please e-mail bflautt@gmail.com or call (662) 392-0740 for pricing and scheduling.

StreetBeat Disclaimer

Distributed by Viestly

Onyx (Nasdaq: ONXX) Trading Higher After Rival Drug Fails Test

Northern, WI 7/20/12 (StreetBeat) – Onyx (Nasdaq: ONXX) shares hit a 52 week high in trading Friday after announcing that its competitor’s drug trials failed to demonstrate statistically significant results on the study. Bristol-Meyers (NYSE: BMY) reported last night that its brivanib, a liver cancer treatment, failed to meet its primary overall survival objective in a Phase III Trial. Onyx’s Nexavar is used to treat liver cancer, and CEO Leerink Swann wrote that brivanib’s failure represents a significant positive for the long-term outlook of Nexavar.

Onyx increased 6% in morning trade Friday, up $4.10 to $72.50. Bristol Meyers decreased 1.75% to $35.51 after reporting these results.

Please contact www.thestreetbeat.com for interest in our latest investor relations platform the “CEO Interview Series” with its host Steve Kanaval. The package includes a one-on-one interview with a seasoned industry professional; published segment to our web site with embedded audio/video file; and a compressed file that can be easily e-mailed out to your current and/or potential investors. Please e-mail bflautt@gmail.com or call (662) 392-0740 for pricing and scheduling.

StreetBeat Disclaimer

Distributed by Viestly

Baker Hughes (NYSE: BHI) +10% After Global Oilfield Growth

Shawshank, VA 7/20/12 (StreetBeat) – Schlumberger Ltd (NYSE:SLB) and Baker Hughes Inc (NYSE:BHI) reported higher-than-expected profits on Friday as revenue significantly increased outside North America. Shares of Baker Hughes shot up 10% after releasing this news.

In June, Baker’s rig count outside North America hit its highest level since 1985 at 1,285 rigs. Schlumberger and Baker, the world’s #1 and #3 oilfield service companies, were enthused by the return of the Gulf of Mexico drilling levels seen before the disastrous spill 2 years ago.

"We are also realizing price improvements as activity ramps up," Baker Hughes Chief Executive Martin Craighead said.

Baker forecasts 8% growth in the international count this year and Schlumberger expects more than 10% growth. Shares of Baker are trading up 10% or $4.29 at $46.04. Schlumberger has increased 2% to $70.01.

Please contact www.thestreetbeat.com for interest in our latest investor relations platform the “CEO Interview Series” with its host Steve Kanaval. The package includes a one-on-one interview with a seasoned industry professional; published segment to our web site with embedded audio/video file; and a compressed file that can be easily e-mailed out to your current and/or potential investors. Please e-mail bflautt@gmail.com or call (662) 392-0740 for pricing and scheduling.

StreetBeat Disclaimer

Distributed by Viestly

EcoloCap (OTCBB: ECOS) Signs Non-Binding LOI with GFE Global

Shawshank, VA 7/20/12 (StreetBeat) – EcoloCap Solutions Inc (OTCBB: ECOS) has signed a non-binding LOI with GFE global Inc to operate and distribute its diesel water emulsion (M-Fuel) production NPUs as well as its proprietary additive. This LOI is subject to further discussion and definitive agreements are expected to be signed by July 25, 2012. In this deal, EcoloCap’s M-Fuel products will be sold in Central American countries as a first step, and then extend to other areas based on penetration targets.

Michael Siegel, President and CEO of EcoloCap, stated: "Central America is a prime target for our technology for two reasons: The high cost of fuel in the area and government environmental regulations for heavy oil users to reduce harmful emissions. Independent tests demonstrate that our M-Fuel technology will reduce the consumption of diesel and other heavy oil by up to 30% and further reduce particulate emissions by over 90%, and NOx by 60%."

Joseph J Black, COO of GFE Global Inc., added: "All Latin American counties with the exception of Venezuela and possibly Brazil are petro fuel NET importers. Many have no oil resources whatsoever. The cost of diesel fuel is well over $4 a gallon in most of these countries and over $5 a gallon in several. We will start introducing the EcoloCap technology in Costa Rica because of their high priced fuel and the government's goal for the country to be carbon neutral by 2021, Costa Rica being true to their reputation as an eco-oriented country. We then plan to expand to Panama and other Latin American countries.”

Please contact www.thestreetbeat.com for interest in our latest investor relations platform the “CEO Interview Series” with its host Steve Kanaval. The package includes a one-on-one interview with a seasoned industry professional; published segment to our web site with embedded audio/video file; and a compressed file that can be easily e-mailed out to your current and/or potential investors. Please e-mail bflautt@gmail.com or call (662) 392-0740 for pricing and scheduling.

StreetBeat Disclaimer

Distributed by Viestly

IDO Security (OTCBB: IDOI) Installs Additional Units in Israeli Government Offices

Atlanta, GA 7/20/12 (StreetBeat) – IDO Security Inc (OTCBB: IDOI) announced yesterday that it has installed additional MagShoe™ systems in government offices throughout Israel. The company develops the innovative MagShoe shoe scanning device with proprietary technology to close the security gap created by the inability of traditional walkthrough metal detectors to scan the area below the knee. This order is a follow-up to successful installation of the MagShoe in 2007 at other Israeli government buildings in Jerusalem, still in use today.

Avishai Rotshtain, IDO Security's Marketing Manager commented, "This order is a vote of confidence by the Israeli security establishment in the MagShoe as a tool of choice to detect metallic objects in lower parts of the body. It is a confirmation of a long and ongoing relationship between Israeli security officials and IDO. The MagShoe's increased presence in Israel's airport and government facilities signify a strong foothold in the country and we hope to see continued success as we further build upon our relationship as we look to expand into other markets including loss prevention."

Please contact www.thestreetbeat.com for interest in our latest investor relations platform the “CEO Interview Series” with its host Steve Kanaval. The package includes a one-on-one interview with a seasoned industry professional; published segment to our web site with embedded audio/video file; and a compressed file that can be easily e-mailed out to your current and/or potential investors. Please e-mail bflautt@gmail.com or call (662) 392-0740 for pricing and scheduling.

StreetBeat Disclaimer

Distributed by Viestly

Sunshine Biopharma (OTCBB: SBFM) Trades up over 10% on News of Manufacturing Adva-27a

Atlanta, GA 7/19/12 (StreetBeat) – Investorideas.com, an investor research portal specializing in sector research including biotech and pharma stocks, issues a trading alert for Sunshine Biopharma Inc. (OTCBB: SBFM). The stock is trading up over 10% on news of manufacturing Adva-27a.

The Company reported that it has engaged Beta Pharma Canada Inc. to manufacture an initial batch of Adva-27a and provide synthesis parameters for future scale-up and large scale manufacturing of the drug. Beta Pharma Canada Inc. is an affiliate of Beta Pharma Inc. with offices and facilities in Connecticut (USA) and Shanghai ( China). Beta Pharma Canada Inc., headquartered in Montreal ( Canada), is a Canadian small-molecule drug discovery and manufacturing company specializing in design, synthesis and process development of novel pharmaceutical compounds. Adva-27a is Sunshine Biopharma’s lead anti-cancer compound which has proven effective at killing Multidrug Resistant Breast Cancer cells (MCF-7/MDR) and Small-Cell Lung Cancer cells (H69AR).

Recent Q&A with Mr. Camille Sebaaly, CFO of Sunshine Biopharma Inc. (OTCBB: SBFM) at Investorideas.com
http://www.investorideas.com/CO/SBFM/news/2012/07021.asp

About Sunshine Biopharma Inc. (OTCBB: SBFM):
Sunshine Biopharma is a pharmaceutical company focused on the research, development and commercialization of drugs for the treatment of various forms of cancer. The Company’s lead compound, Adva-27a targets aggressive forms of cancer.
www.sunshinebiopharma.com

About InvestorIdeas.com:
InvestorIdeas.com is a leader in investor stock research by sector, including biotech and pharma stocks. Visit the biotech portal within Investor Ideas: www.biotechindustrystocks.com

Follow Investorideas.com on Twitter http://twitter.com/#!/Investorideas
Follow Investorideas.com on Facebook http://www.facebook.com/Investorideas

Disclaimer/ Disclosure : The Investorideas.com is a third party publisher of news and research Our sites do not make recommendations, but offer information portals to research news, articles, stock lists and recent research. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. This site is currently compensated by featured companies, news submissions and online advertising. Disclosure: A third party on behalf of SBFM compensated Investorideas.com for news release publishing and distribution: one hundred thousand 144 shares for three months starting June 26th

BC Residents and Investor Disclaimer : Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894

800-665-0411 - Source – www.Investorideas.com

Please contact www.thestreetbeat.com for interest in our latest investor relations platform the “CEO Interview Series” with its host Steve Kanaval. The package includes a one-on-one interview with a seasoned industry professional; published segment to our web site with embedded audio/video file; and a compressed file that can be easily e-mailed out to your current and/or potential investors. Please e-mail bflautt@gmail.com or call (662) 392-0740 for pricing and scheduling.

StreetBeat Disclaimer

Distributed by Viestly

Tim Participações (NYSE: TSU) Blindsided with the Blockage of Sales in 19 States

Atlanta, GA 7/19/12 (StreetBeat) – TIM Participações SA (NYSE: TSU) was blindsided today with Anatel blocking the sale of new lines in 19 states. Tim is the only operator in today’s market that sells its phones unlocked and without loyalty penalty. In 2011, the company became the 2nd largest mobile operator in the country.

Tim said, "The decision was apparently based on data and indicators different from those usually established by Anatel it self to track the performance of the network. The presented measure took into account, for example, the percentage difference in each state between the worst operator and the others' average in complaints to the Anatel's call center, a measure until now unknown and does not necessarily reflect the quality of the network...TIM reaffirms that it is developing a set of infrastructure projects to continue to provide innovative services to customers, supporting the growth and capturing the opportunities that market offers...The Company is also working on upgrading equipment, doubling the speed of the infrastructure of mobile Internet access to 42 Mbps, or HSPA+, an intermediate step between 3G and 4G."

Shares are trading down 8% or $2.08 at $21.65 Thursday.

Please contact www.thestreetbeat.com for interest in our latest investor relations platform the “CEO Interview Series” with its host Steve Kanaval. The package includes a one-on-one interview with a seasoned industry professional; published segment to our web site with embedded audio/video file; and a compressed file that can be easily e-mailed out to your current and/or potential investors. Please e-mail bflautt@gmail.com or call (662) 392-0740 for pricing and scheduling.

StreetBeat Disclaimer

Distributed by Viestly

Five Below (Nasdaq: FIVE) Trading +55% on IPO Debut

Shawshank, VA 7/19/12 (StreetBeat) – Five Below (Nasdaq: FIVE) pops 55% in its IPO debut on the Nasdaq today. The company priced its IPO at $17, the top of its IPO price range, and is currently trading at $26.44.

9.6 million shares are being sold in this IPO, split between the company and shareholders. The underwriters include Goldman Sachs, Barclays, and Jefferies.

The Wall Street Journal comments on IPOS this year that this will help “the already high average for first-day IPO pops seen this year and set a high bar for a list of other IPOs coming this week, including long awaited Kayak Software and Palo Alto Networks. Palo Alto also boosted its price range this week.”

Please contact www.thestreetbeat.com for interest in our latest investor relations platform the “CEO Interview Series” with its host Steve Kanaval. The package includes a one-on-one interview with a seasoned industry professional; published segment to our web site with embedded audio/video file; and a compressed file that can be easily e-mailed out to your current and/or potential investors. Please e-mail bflautt@gmail.com or call (662) 392-0740 for pricing and scheduling.

StreetBeat Disclaimer

Distributed by Viestly

Psivida Corp (Nasdaq: PSDV) Soars As Eye Device Moves to Late-Stage Trials

Palm Beach, FL 7/19/12 (StreetBeat) – Shares of Psivida Corp (Nasdaq: PSDV) surged 37% Thursday following the U.S. health regulators clearance of its experimental eye insert to skip initial studies and proceed directly to late-stage trials. The insert is a sustained-release device injected into the back of the eye and aims to treat posterior uveitis. Posterior Uveitis, classified as the 3rd largest cause of blindness in the US, is an inflammatory disease of one of the layers of the eye.

"As the same micro-insert was used in the Iluvien trials, we expect to observe a comparable side-effect profile in uveitis patients as was seen in diabetic macular edema patients," Chief Executive Paul Ashton said. Iluvien has been rejected twice by the FDA, but is currently approved to treat retinal swelling in diabetic patients in the UK, Austria, France, and Portugal.

Psivida added that “since the experimental insert delivers the same drug as its other insert Retisert, which is FDA-approved to treat posterior uveitis, the company expects to see favorable efficacy in the late-stage studies”.

Shares are currently trading at $2.94, up $.80 or 37%.

Please contact www.thestreetbeat.com for interest in our latest investor relations platform the “CEO Interview Series” with its host Steve Kanaval. The package includes a one-on-one interview with a seasoned industry professional; published segment to our web site with embedded audio/video file; and a compressed file that can be easily e-mailed out to your current and/or potential investors. Please e-mail bflautt@gmail.com or call (662) 392-0740 for pricing and scheduling.

StreetBeat Disclaimer

Distributed by Viestly

Pool Corp (Nasdaq: POOL) Cut Forecast, shares Down 11%

Palm Beach, FL 7/19/12 (StreetBeat) – Pool Corp (Nasdaq: POOL) shares are trading down 11% after posting lower- than-expected quarterly results. The swimming pool distributor cites pricing pressures and unfavorable changes in customer mix for this decline. The company cut its upper end fiscal 2012 earnings forecast from $1.85 to $1.82 per share.

Net Income Q2 rose to $64.9 million ($1.34 per share) from $58.6 million ($1.19 per share) a year earlier. Revenue rose 7% to $757.2 million. According to Thomson Reuters, analysts were expecting earnings of $1.35 per share on $770.1 million.

Pool Corp’s stock touched a low of $36 in early trading, currently trading at down $3.35 at $37.17.

Please contact www.thestreetbeat.com for interest in our latest investor relations platform the “CEO Interview Series” with its host Steve Kanaval. The package includes a one-on-one interview with a seasoned industry professional; published segment to our web site with embedded audio/video file; and a compressed file that can be easily e-mailed out to your current and/or potential investors. Please e-mail bflautt@gmail.com or call (662) 392-0740 for pricing and scheduling.

StreetBeat Disclaimer

Distributed by Viestly

Georgia Gulf (NYSE: GGC) Getting PPG Unit in $2 Bill Deal

Orlando, FL 7/19/12 (StreetBeat) – Shares of Georgia Gulf (NYSE:GGC) are trading up 14% this morning after reaching a deal for a merger with PPG Industries (NYSE:PPG), giving it a large stake and control in a newly formed chemicals player. PPG Industries plans to spinoff its chemicals operations and merge it with Georgia Gulf, with PPG shareholders getting 50.%% and Georgia Gulf will have 49.5%.

Earlier this year, Georgia fought off a hostile takeover attempt from rival Westlake Chemical, saying that it was doing just fine and the $35 offer price wasn’t fair. The transaction between Georgia Gulf and PPG is worth $2.1 billion, with PPG getting $900 million in cash and $1 billion in shares of Georgia Gulf. The combined company will have about $5 billion in annual revenues and be the #3 producer in North America of chlor-alkali, a chemical used in chlorine, PVC piping, and other uses.

Georgia Gulf shares jumped 14% to $33.04 in trading Thursday while PPG added 7% to $111.63.

Please contact www.thestreetbeat.com for interest in our latest investor relations platform the “CEO Interview Series” with its host Steve Kanaval. The package includes a one-on-one interview with a seasoned industry professional; published segment to our web site with embedded audio/video file; and a compressed file that can be easily e-mailed out to your current and/or potential investors. Please e-mail bflautt@gmail.com or call (662) 392-0740 for pricing and scheduling.

StreetBeat Disclaimer

Distributed by Viestly

Mellanox Tech (OTCBB:MLNX) Hits Lifetime High in Morning Trade

Northern, WI 7/19/12 (StreetBeat) – Mellanox Technologies Inc (OTCBB: MLNX) reached its lifetime high in trading today after announcing an impressive quarterly profit that beat analyst expectations. At least 10 brokerages raised their price targets on the company’s stock, with Harel Finance analyst Rami Rozen stating “this is the second quarter in a row that Mellanox breaks every growth record possible and raises the level of investors’ expectations to new heights.”

Mellanox designs chips for the InfiniBand data exchange standard that regulates the way servers and data systems communicate with each other. Its quarterly growth can be contributed to the strong storage, data, and cloud trends we are seeing today. "In InfiniBand (IB), Mellanox is a generation ahead of Intel Corp (INTC) and clearly benefiting from IB gaining share in various servers/storage platforms," Needham & Co wrote in a note. Its clientele include big names such as Hewlett-Packard Co (NYSE: HPQ) and IBM Corp (NYSE: IBM).

Shares of the company increased 36.73% this morning, trading up $24.38 at $90.76. The company has seen its stock more than double in the past year alone.

Please contact www.thestreetbeat.com for interest in our latest investor relations platform the “CEO Interview Series” with its host Steve Kanaval. The package includes a one-on-one interview with a seasoned industry professional; published segment to our web site with embedded audio/video file; and a compressed file that can be easily e-mailed out to your current and/or potential investors. Please e-mail bflautt@gmail.com or call (662) 392-0740 for pricing and scheduling.

StreetBeat Disclaimer

Distributed by Viestly

Emrise (OTCBB: EMRI) Receives $1.5 Million Electronic Devices Order

Northern, WI 7/19/12 (StreetBeat) – Emrise Coroporation (OTCBB:EMRI) announced yesterday that it received a $1.5 million order for its products to be used throughout commercial aircrafts’ In-Flight Entertainment and Connectivity (IFE&C) systems. The company will provide electronic devices and subsystems for the IFE&C systems, following a recent $5.4 million order and increasing the total value of major IFE&C electronic device orders to more than $8 million booked to date in 2012. This order is from a longstanding customer and will have shipments starting in this year’s fourth quarter and continue through 2014

The demand for these advanced IFE&C systems have continually increased with the desire for new technologies. They can deliver to the passenger seay a variety of multimedia entertainment features including live satellite TV and a number of connectivity features such as GSM for in-flight mobile phone use and Broadband for access to Internet, e-mail, and messaging services. Emrise has been seeing ongoing grown in this IFE&C market, and CEO Carmine Oliva noted that the number of orders is up approximately 144% from the comparable period in 2011.

"Today we are selling electronic devices to an increasing number of customers in the IFE&C market," Oliva said. "This larger and more diverse customer base further opens up the IFE&C market potential for the Company, which is also contributing to our growing backlog of orders."

Please contact www.thestreetbeat.com for interest in our latest investor relations platform the “CEO Interview Series” with its host Steve Kanaval. The package includes a one-on-one interview with a seasoned industry professional; published segment to our web site with embedded audio/video file; and a compressed file that can be easily e-mailed out to your current and/or potential investors. Please e-mail bflautt@gmail.com or call (662) 392-0740 for pricing and scheduling.

StreetBeat Disclaimer

Distributed by Viestly

EncounterCare Solutions (OTCBB: ECSL) Forms New Subsisidary

Northern, WI 7/18/12 (StreetBeat) – EncounterCare Solutions Inc (OTCBB:ECSL) has formed a new subsidiary Cyber Fuels, Inc, and has also partnered for addiction recovery treatment. With the Cyber Fuel news, EncounterCare plans on having it focus on managing new market initiatives in energy. Energy will be a major part of EncounterCare’s business plan in this fiscal year, and this new subsidiary provides an exciting opportunity for success in this area. The addition of Cyber Fuels, Inc. marks EncounterCare Solutions, Inc.'s entrance into the field of alternative fuels and is the parent companies third market of business.

One of EncounterCare’s other subsidiaries, CyberCare Health Network, has announced its arrangement with Addiction Reach, Inc to begin marketing its new Alcohol and Drug Addiction monitoring program in October. This program is an integral part of CyberCare’s therapy program for at home concierge addiction recovery treatment. The program will be debuted at the “MOMENT OF CHANGE” annual conference on October 7, 2012 at the Breakers Hotel in Palm Beach, FL.

Sue Merklin, President of Addiction Reach Inc., stated, "Patient monitoring and accountability is essential for long term addiction recovery."

EncounterCare Solutions Inc is trading up 9.38% at $0.35 Midday Wednesday.

Please contact www.thestreetbeat.com for interest in our latest investor relations platform the “CEO Interview Series” with its host Steve Kanaval. The package includes a one-on-one interview with a seasoned industry professional; published segment to our web site with embedded audio/video file; and a compressed file that can be easily e-mailed out to your current and/or potential investors. Please e-mail bflautt@gmail.com or call (662) 392-0740 for pricing and scheduling.

StreetBeat Disclaimer

Distributed by Viestly

mPhase (OTCBB: XDSL) to Partner with Stevens IT on Research and Business Opportunities

Atlanta, GA 7/18/12 (StreetBeat) – mPhase Technologies Inc (OTCBB:XDSL) and Stevens Institute of Technology have jointly agreed to pursue business opportunities with government and industry as well as research and development projects. The companies will focus on the design and fabrication of an advanced battery technology utilizing intellectual property and resources from both parties. They plan to try to advance mPhase’s Smart NanoBattery Technology with Steven’s graphene-based inkjet printing method for printing electrodes and electronic circuits.

"mPhase is excited to explore the possibilities of integrating Stevens' leading position in the inkjet printing of energy storage devices using graphene with mPhase's Smart NanoBattery Technology," said Ronald A. Durando, CEO of mPhase Technologies.

"Stevens looks forward to continuing its relationship with mPhase by pursuing this exciting opportunity," added Christos Christodoulatos, Associate Provost of Stevens, Office of Academic Entrepreneurship.

mPhase Technologies is trading up 5.88% Wednesday.

Please contact www.thestreetbeat.com for interest in our latest investor relations platform the “CEO Interview Series” with its host Steve Kanaval. The package includes a one-on-one interview with a seasoned industry professional; published segment to our web site with embedded audio/video file; and a compressed file that can be easily e-mailed out to your current and/or potential investors. Please e-mail bflautt@gmail.com or call (662) 392-0740 for pricing and scheduling.

StreetBeat Disclaimer

Distributed by Viestly

Vivus Inc (NasdaqL VVUS) Gets FDA Approval on Weight Loss Drug

Atlanta, GA 7/18/12 (StreetBeat) – Vivus Inc (Nasdaq: VVUS) is trading up 13.6% or $3.60 at $30.06 following FDA approval of its one a day weight loss drug, Qsymia.

Vivus is a biopharmaceutical company focusing its studies in obesity, sleep apnea, diabetes, and sexual health. The Qsymia drug, with an expected fourth quarter 2012 release, is the first drug of its kind to be approved by the FDA.

"Qsymia is the first FDA-approved once daily combination treatment for patients struggling with obesity," said Peter Tam, president of Vivus in a prepared statement. "The degree and severity of obesity and the lack of effective pharmacological interventions that we face as a society were two primary reasons for the development of Qsymia. We are pleased with FDA's decision today because patients and physicians now have another treatment option available to them."

Please contact www.thestreetbeat.com for interest in our latest investor relations platform the “CEO Interview Series” with its host Steve Kanaval. The package includes a one-on-one interview with a seasoned industry professional; published segment to our web site with embedded audio/video file; and a compressed file that can be easily e-mailed out to your current and/or potential investors. Please e-mail bflautt@gmail.com or call (662) 392-0740 for pricing and scheduling.

StreetBeat Disclaimer

Distributed by Viestly

Rovi Corp (Nasdaq: ROVI) Shares Crash on Weak Forecast

Shawshank, VA 7/18/12 (StreetBeat) – Rovi Corp (Nasdaq: ROVI) has released a bleak forecast for the year ahead. The company estimates 2Q results below analyst expectations and its cut forecast comes form an anticipated weakening of sales in its consumer electronics division. Two brokerages have downgraded its stock as a result, and Rovi shares have, consequently, slumped 35% today. Rovi’s shares were down $6.10 at $11.50, making them the top percentage loser on the Nasdaq Wednesday morning.

Electronics Manufacturers such as Apple Inc and Sony Corp use Rovi’s software to play various digital media formats on home entertainment devices. Rovi has been affected by the weakening demand for devices that use its technology and a slow pace of license renewals and sales.

"Rovi has not executed effectively recently and is now, in our view, facing uncertainty surrounding the timing of new license agreements as well as weakness in its underlying market," BMO Capital Markets analyst Edward Williams wrote in a note to clients.

Please contact www.thestreetbeat.com for interest in our latest investor relations platform the “CEO Interview Series” with its host Steve Kanaval. The package includes a one-on-one interview with a seasoned industry professional; published segment to our web site with embedded audio/video file; and a compressed file that can be easily e-mailed out to your current and/or potential investors. Please e-mail bflautt@gmail.com or call (662) 392-0740 for pricing and scheduling.

StreetBeat Disclaimer

Distributed by Viestly

Galena Bio (Nasdaq: GALE) +20% on U.S. Patent Issuance

Shawshank, VA 7/18/12 (StreetBeat) – Galena Biopharma Inc (Nasdaq:GALE) has been issued a key patent from the U.S. Patent and Trademark Office (USPTO) covering the use of its product candidate, NeuVaxTM, for inducing immunity to breast cancer recurrence in patients having low-to-intermediate IHC levels of 1+ or 2+ and a FISH rating of less than 2.0. This patent strengthens NeuVax’s Intellectual Property and provides the company with exclusivity until 2028. As much as 80% of breast cancer patients who do not qualify for Herceptin ® Therapy represent a significant unmet medial need, of which NeuVax is trying to fulfill.

"As we continue to make progress with the clinical development of NeuVax, issuance of this patent from the USPTO underscores our commitment to support and advance our proprietary oncology pipeline," stated Mark J. Ahn, Ph.D., President and CEO.

Gale's stock has surged 20% following this news, up 35 cents to $2.06.

Please contact www.thestreetbeat.com for interest in our latest investor relations platform the “CEO Interview Series” with its host Steve Kanaval. The package includes a one-on-one interview with a seasoned industry professional; published segment to our web site with embedded audio/video file; and a compressed file that can be easily e-mailed out to your current and/or potential investors. Please e-mail bflautt@gmail.com or call (662) 392-0740 for pricing and scheduling.

StreetBeat Disclaimer

Distributed by Viestly